Introduction
============

*Salmonella* spp. has long been recognised as a common cause of foodborne gastroenteritis in humans ([@b6-bjm-44-057]) and responsible for significant economic losses in the food industry ([@b14-bjm-44-057]). Although *Salmonella* gastroenteritis may be caused by any of more than 2,500 serotypes ([@b15-bjm-44-057]), *S.* Enteritidis remains one of the main causes of foodborne illness, and is considered one of the most important pandemic zoonosis produced under natural conditions ([@b1-bjm-44-057]; [@b20-bjm-44-057]). It has been reported that a well characterised pathogenic *S.* Enteritidis strain (SE86) was involved in many foodborne outbreaks in the State of Rio Grande do Sul (RS), the southernmost state in Brazil ([@b10-bjm-44-057]; [@b21-bjm-44-057]; [@b23-bjm-44-057]). In addition, SE86 has been reported to undergo acid adaptation, as characterised by: increased acid and thermal resistance ([@b1-bjm-44-057]) higher survival rates in simulated gastric fluid ([@b3-bjm-44-057]), and better intestinal colonisation in mice ([@b4-bjm-44-057]; [@b19-bjm-44-057]; [@b25-bjm-44-057]).

The reduction of infections caused by foodborne pathogens such as *S*. Enteritidis is of great importance for public health. Treatment of salmonellosis is carried out mainly with fluid replacement, and the antibiotics are only recommended for extra-intestinal infections and exceptional cases. The possibility of using probiotic bacteria for protection against enteropathogenic infections has been considered ([@b11-bjm-44-057]; [@b29-bjm-44-057]). Probiotics are defined as live microorganisms that, when ingested in appropriate amounts, confer a health benefit to the host ([@b8-bjm-44-057]). Probiotic bacteria can play a role in defense and recovery from enteropathogenic infections ([@b5-bjm-44-057]; [@b30-bjm-44-057]), especially by protecting the host from enteropathogen colonization, and by modulating the host immune response ([@b26-bjm-44-057]).

The most widely used probiotic bacteria, and more relevant to the prevention of tissue infection by enteropathogens are *Bifidobacterium* and *Lactobacillus* ([@b5-bjm-44-057]; [@b9-bjm-44-057]; [@b12-bjm-44-057]). Among the *Lactobacillus* species*, L. acidophilus, L. plantarum, L. bulgaricus, L. casei,* and *L. rhamnosus* have been frequently used. These Gram positive bacteria are natural inhabitants of the gastrointestinal tract, which they colonize by adhering to the intestinal epithelium, where they produce lactic acid and effectively act as probiotics ([@b3-bjm-44-057]). *L. acidophilus* has been reported to be capable of stimulating the defense mechanisms of the immune system by colonizing the gastrointestinal tract and preventing the adhesion of many enterotoxigenic and enteroinvasive bacteria ([@b21-bjm-44-057]).

Based on these findings, the goal of this study was to evaluate the ability of a probiotic *L. acidophilus* LA10 to exert antagonistic effects against *S.* Enteritidis SE86 in mice.

Materials and Methods
=====================

Animal handling and experimental protocol
-----------------------------------------

Conventional male Swiss mice, 21--23 days of age, were used in this work. The animals were individually housed, supplied with potable water and commercial animal feed *ad libitum*, at 22 °C ± 2 °C, with 65% at 70% humidity and alternate 12 h periods of light and dark. All experimental procedures were carried out according to standards set forth by the Ethics and Research Council of the Universidade do Oeste de Santa Catarina, protocol number 017/2008.

Bacterial strains and culture conditions
----------------------------------------

*S.* Enteritidis SE86 was isolated from a cabbage involved in a foodborne outbreak occurred in 1999 in Rio Grande do Sul (RS) State, in Brazil. This strain shows the same genotypic profile as more than 90% of the *S.* Enteritidis involved in foodborne salmonellosis in RS State during the period between 1999 and 2002 ([@b10-bjm-44-057]; [@b22-bjm-44-057]). Before the experiments, the SE86 was stored at −18 °C in 50% (v/v) glycerol. Working cultures were kept at 4 °C on BHI agar plates (Merck, Darmstadt, Germany), and subcultured in tubes containing BHI (Merck, Darmstadt, Germany) broth at 37 °C for 24 h.

Capsules of liophylized *L. acidophilus* LA10 were acquired in a pharmacy located in São Miguel do Oeste, State of Santa Catarina, Brazil. The capsule contents were diluted in 1 mL of sterile distilled water resulting in 10^8^ cells/mL.

Treatments and experimental infection
-------------------------------------

A single dose of 0.1 mL containing 10^8^ viable cells of SE86 was orally administered to each mice. A dose of 0.1 mL containing 2 × 10^8^ cells/mL of *L. acidophilus* LA10 was administered by gavage ([@b2-bjm-44-057]).

As a negative control, Group 1 mice were only administered sterile saline solution. As a positive control, Group 2 mice were administered only *S.* Enteritidis SE86. Mice from both groups were sacrificed after 10 days.

Experimental groups were divided into two (Group 3 and Group 4). Group 3 mice were first challenged with *S.* Enteritidis SE86, and after 10 days, were treated with *L. acidophilus* LA10. Group 4 mice were first administered with *L. acidophilus* LA10*,* and after 10 days, were challenged with *S.* Enteritidis SE86. Both groups were sacrificed 10 days after administration of the last microorganism.

Microbial counts
----------------

Fresh mice feces (1 g) were collected on the tenth day after administration of the microorganisms. Portions of the gastrointestinal tract (0.1 g of ileum and colon) were sampled at the tenth day after mice were sacrificed by cervical dislocation. The ileum and colon portions were homogenized into tubes containing 9.99 mL of buffered saline peptone water, while feces were homogenized in 9 mL of the same solution. Samples were homogenized for 2 min using an automatic mixer. Decimal dilutions were prepared and *L. acidophilus* LA10 cell counts were performed by spreading 1 mL of diluted feces (0.1 mL) or intestinal portions (0.01 mL) on plates containing Agar-Man-Rogosa Sharpe (MRS) (Merck, Darmstadt, Germany) and the plates were incubated at 36 °C for 48--72 h in a microaerophilic incubator ([@b21-bjm-44-057]; [@b32-bjm-44-057]). Typical colonies were confirmed using biochemical tests ([@b18-bjm-44-057]).

Microbiological quantification of SE86 was carried out using the most probable number (MPN) method ([@b4-bjm-44-057]).

Statistical analysis
--------------------

Statistical analysis was performed using the Chi-square and Pearson correlation coefficient to assess population levels. The level of significance was set at p ≤ 0.05 using the statistical package SPSS, Version 12 for Windows.

Results and Discussion
======================

Our results confirmed that mice from Group 1 (negative control) did not contain SE86 in the gastrointestinal tract or in feces. In contrast, in Group 2 mice (positive control) challenged with SE86, the colon was clearly colonized, with counts between \< 30/g and \> 11000/g (arithmetic mean, 3760 MPN/g). Feces from these Group 2 mice displayed counts varying from 9.2 to \> 1100/g (arithmetic mean, 593 MPN/g), and ileum counts varying from \< 30/g to 230/g (arithmetic mean, 78 MPN/g). Similar results were reported by [@b25-bjm-44-057], who found that SE86 was able to infect the gastrointestinal tract of rats and spread into the feces.

According to [@b17-bjm-44-057], salmonellosis in the rat has many similarities with the disease in humans. The study of [@b16-bjm-44-057] showed that, immediately after infection, *Salmonella* were found preferentially associated with Peyer's patches in the terminal ileum, which is thought to be the main site of colonization/invasion. Thus, rats may be useful to study mechanisms of infection by these pathogenic bacteria ([@b28-bjm-44-057]). [@b27-bjm-44-057] reported that *Salmonella* tend to remain in the gastrointestinal tract during all stages of infection, and that a relatively high number of cells persist in the intestine after contamination with the pathogenic bacteria. The same researchers [@b27-bjm-44-057] suggested that *S.* Enteritidis is able to translocate to the small intestine, and induce gene expression changes in the ileal mucosa and Peyer's patches. However, the effects of *Salmonella* on colonic gene expression *in vivo* are largely unknown.

In Group 3 (which was first challenged with *S.* Enteritidis SE86 and after 10 days treated with *L. acidophilus* LA10 we observed that the mice showed no SE86 in their intestinal portions (either the ileum or colon). In this group, the mice eliminated the pathogenic bacteria in their feces ([Table 1](#t1-bjm-44-057){ref-type="table"}). The correlation between counts of *L. acidophillus* LA10 and *S.* Enteritidis SE86 was inversely proportional ([Figure 1](#f1-bjm-44-057){ref-type="fig"}), with a medium high negative correlation for feces (−0.6831), and medium negative correlation in the colon (−0.2822) and ileum (−0.3893).

In Group 4 (which was first treated with *L. acidophilus* LA10 and after 10 days challenged with *S.* Enteritidis SE86), colonization by pathogenic bacteria was higher in the colon, followed by the ileum and feces ([Table 2](#t2-bjm-44-057){ref-type="table"}). The correlation between counts of *L. acidophilus* LA10 and *S.* Enteritidis SE86 was again inversely proportional ([Figure 1](#f1-bjm-44-057){ref-type="fig"}) as in Group 3, with a medium high negative correlation in the feces (−0.5524), and a medium negative correlation in the colon (−0.2011) and ileum (−0.1527).

[@b13-bjm-44-057] reported that intestinal colonization by *S.* Enteritidis is concentrated in the distal ileum and caecum, and may be detected by fecal excretion. [@b16-bjm-44-057] suggested that the terminal ileum is the primary site of *Salmonella* infection. However, [@b27-bjm-44-057] showed that, in addition to the ileum, the colon mucosa is clearly a target for *Salmonella* infection, which could explain the increased colonization by *S.* Enteritidis SE86 found in the colon in this study (group 4). Also, [@b33-bjm-44-057], found multiple ulcerations caused by *Salmonella* in the distal transverse colon and proximal descending colon in biopsies performed on humans with salmonellosis, highlighting the importance of studies investigating the infection process of this bacterium in the gastrointestinal tract, and specifically in the colon.

Comparing results obtained in Groups 3 and 4, we observed that after treatment with *L. acidophilus* LA10, the MPN of *S.* Enteritidis SE86 in the latter group was higher than in the former, although the counts of *L. acidophilus* LA10 remained in both groups between 10^6^ and 10^7^ cfu/g. These data were also confirmed statistically, and the correlation coefficient was higher in Group 3 in all intestinal portions evaluated, as well as in the feces ([Figure 1](#f1-bjm-44-057){ref-type="fig"}).

The fact that the NMP/g of SE86 was lower in the experimental group first challenged with *S.* Enteritidis SE86 and after 10 days treated with *L. acidophilus* LA10 (Group 3) suggests that *L. acidophilus* LA10 is able to proliferate in the conditions of the gastrointestinal tract and colonize in high population levels in the gut ecosystem, demonstrating that this probiotic is an effective antagonist against *S.* Enteritidis SE86. The antagonistic activity of lactic acid bacteria against *Salmonella* infection has been studied elsewhere ([@b7-bjm-44-057]). Statistically, the best inverse correlation results were found in this group ([Figure 1](#f1-bjm-44-057){ref-type="fig"}), emphasising that the administration of *L. acidophilus* LA10 after infection by *S.* Enteritidis SE86 showed better antagonist effects against this pathogenic bacteria ([Tables 1](#t1-bjm-44-057){ref-type="table"} and [2](#t2-bjm-44-057){ref-type="table"}).

The protection offered by *L. acidophilus* LA10 against pathogenic bacteria challenge is probably due to additional protection mechanisms provided by these intestinal microbiota and their properties as bio-therapeutic agents ([@b23-bjm-44-057]). Similar results were reported by [@b21-bjm-44-057] and [@b31-bjm-44-057] using *L. acidophilus* and *Bifidobacterium,* respectively. These authors observed that probiotics produce antagonistic substances against *S.* Enteritidis. However, this protection is not due to a reduction of the pathogenic populations in the intestines, but instead this bio-therapeutic agent may act through other protective mechanisms such as immunomodulation. In addition, other properties, such as competition for adherence sites, may also explain the protective effects of *Lactobacillus* against enteropathogenic bacteria ([@b23-bjm-44-057]).

Conclusions
===========

In conclusion, *L. acidophilus* LA10 showed antagonistic effect against *S.* Enteritidis SE86, suggesting that this probiotic can be used as a therapeutic tool against salmonellosis. This is an interesting result since *S*. Enteritidis SE86 has been identified as responsible for salmonellosis outbreaks since 1999 in Rio Grande do Sul State, southern Brazil.

Furthermore, the administration of probiotics during infection by *S*. Enteritidis SE86 (treatment) seems to be more effective than administration before infection (prevention).
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###### 

Relationship between counts of *Salmonella* Enteritidis SE86 and *Lactobacillus acidophilus* LA10 in portions of the intestine and feces of mice from the group initially challenged with *Salmonella* Enteritidis SE86 and treated after 10 days with *Lactobacillus acidophilus* LA10.

  Animals    *Salmonella* Enteritidis SE86 (MPN/g)              *Lactobacillus acidophilus* LA10 (CFU/g)                                          
  ---------- -------------------------------------------------- ------------------------------------------ -------- -------------- -------------- --------------
  Mice \#1   \< 30[\*](#tfn1-bjm-44-057){ref-type="table-fn"}   \< 30                                      7.4      3.76 × 10^6^   1.0 × 10^2^    8.83 × 10^7^
  Mice \#2   \< 30                                              \< 30                                      43       7.28 × 10^5^   7.65 × 10^3^   3.05 × 10^7^
  Mice \#3   \< 30                                              \< 30                                      23       1.99 × 10^6^   2.75 × 10^8^   2.15 × 10^7^
  Mice \#4   \< 30                                              \< 30                                      \< 3.0   4.21 × 10^6^   1.15 × 10^4^   5.4 × 10^7^
  Mice \#5   430                                                930                                        \< 3.0   1.43 × 10^6^   2.8 × 10^7^    1.85 × 10^7^
  Mice \#6   \< 30                                              \< 30                                      \< 3.0   2.95 × 10^6^   1.34 × 10^8^   4.1 × 10^7^

For statistical analysis purposes it was considered the maximum number of 11000 for counts that have the sign \> (greater than) and minimum of 3.0 for counts that have the sign \< (less than) to feces and portions of the intestine, respectively.

###### 

Relationship between counts of *Salmonella* Enteritidis SE86 and *Lactobacillus acidophilus* LA10 in the gastrointestinal tract and feces of mice from the group treated initially with *Lactobacillus acidophilus* LA10 and after 10 days challenged with *Salmonella* Enteritidis SE86.

  Animals    *Salmonella* Enteritidis SE86 (MPN/g)   *Lactobacillus acidophilus* LA10 (CFU/g)                                            
  ---------- --------------------------------------- ------------------------------------------ -------- -------------- ---------------- --------------
  Mice \#1   92                                      \> 11000                                   23       1.38 × 10^7^   4.75 × 10^4^     1.14 × 10^8^
  Mice \#2   \< 30                                   61                                         \< 3.0   2.51 × 10^7^   8.45 × 10^4^     2.93 × 10^7^
  Mice \#3   2100                                    \< 30                                      460      4.55 × 10^6^   6.75 × 10^6^     1.16 × 10^7^
  Mice \#4   \< 30                                   \< 30                                      \< 3.0   1.92 × 10^6^   1.2 × 10^4^      2.45 × 10^7^
  Mice \#5   \< 30                                   \< 30                                      23       3.44 × 10^5^   \< 1.0 × 10^2^   1.08 × 10^8^
  Mice \#6   \< 30                                   200                                        240      9.44 × 10^5^   \< 1.0 × 10^2^   1.9 × 10^7^

For statistical analysis purposes it was considered the maximum number of 11000 for counts that have the sign \> (greater than) and minimum of 3.0 for counts that have the sign \< (less than) to feces and portions of the intestine, respectively.
